W A Davis1, M W Knuiman, D Hendrie, T M E Davis. 1. University of Western Australia, School of Medicine and Pharmacology, Western Australia, Australia. wdavis@cyllene.uwa.edu
Abstract
BACKGROUND: The cost of diabetes is high for both the individual and society. Future health-care planning requires patient-level diabetes-attributable health-care cost data that have not previously been available for Australia. AIM: To determine Australian national direct diabetes-attributable health-care costs for known type 2 diabetes in 2000 and project these to 2051. METHODS: A total of 1294 patients with type 2 diabetes was recruited to the Fremantle Diabetes Study between 1993 and 1996. A bottom-up, prevalence-based approach using diabetes-attributable costs provided average annual per patient health-care costs (in year 2000 A$). Costs were extrapolated to 2051 using Australian type 2 diabetes prevalence figures and Australian Bureau of Statistics population projections, assuming that prevalence rates (i) remain at current levels and (ii) rise steadily. RESULTS: Total annual direct diabetes-attributable health-care costs in 2000 in Australia for people > or =25 years with known type 2 diabetes were estimated at A$636 million. As a result of ageing, the number of people with type 2 diabetes will double between 2000 and 2051 with a 2.5-fold increase in diabetes-attributable health-care costs. If obesity and inactivity prevalence rates continue to rise, prevalence rates of type 2 diabetes will further increase. The number of people with type 2 diabetes in 2051 may be 3.5 times higher than in 2000 with a 3.7-fold cost increase. CONCLUSIONS: The financial burden of treating type 2 diabetes could quadruple by 2051 unless more is done to prevent type 2 diabetes and its complications. A smaller proportion of the population will have the capacity to fund these rising health-care costs.
BACKGROUND: The cost of diabetes is high for both the individual and society. Future health-care planning requires patient-level diabetes-attributable health-care cost data that have not previously been available for Australia. AIM: To determine Australian national direct diabetes-attributable health-care costs for known type 2 diabetes in 2000 and project these to 2051. METHODS: A total of 1294 patients with type 2 diabetes was recruited to the Fremantle Diabetes Study between 1993 and 1996. A bottom-up, prevalence-based approach using diabetes-attributable costs provided average annual per patient health-care costs (in year 2000 A$). Costs were extrapolated to 2051 using Australian type 2 diabetes prevalence figures and Australian Bureau of Statistics population projections, assuming that prevalence rates (i) remain at current levels and (ii) rise steadily. RESULTS: Total annual direct diabetes-attributable health-care costs in 2000 in Australia for people > or =25 years with known type 2 diabetes were estimated at A$636 million. As a result of ageing, the number of people with type 2 diabetes will double between 2000 and 2051 with a 2.5-fold increase in diabetes-attributable health-care costs. If obesity and inactivity prevalence rates continue to rise, prevalence rates of type 2 diabetes will further increase. The number of people with type 2 diabetes in 2051 may be 3.5 times higher than in 2000 with a 3.7-fold cost increase. CONCLUSIONS: The financial burden of treating type 2 diabetes could quadruple by 2051 unless more is done to prevent type 2 diabetes and its complications. A smaller proportion of the population will have the capacity to fund these rising health-care costs.
Authors: G Bruno; L Karaghiosoff; F Merletti; G Costa; M De Maria; F Panero; O Segre; P Cavallo-Perin; R Gnavi Journal: Diabetologia Date: 2008-03-04 Impact factor: 10.122
Authors: John Furler; Justin W S Hii; Danny Liew; Irene Blackberry; James Best; Leonie Segal; Doris Young Journal: BMC Fam Pract Date: 2013-03-08 Impact factor: 2.497